Durch Arbeiten im Rechenzentrum kann die Erreichbarkeit am 20. und 21. April 2024 kurzfristig eingeschränkt sein.
Download
GOeG_PPI_PriceStudy_2017_StudyProtocol.pdf 707,65KB
WeightNameValue
1000 Titel
  • Price comparison of high-cost medicines ..., 2017
1000 Unterreihe
  • Study protocol
1000 Verantwortlich
  • owner and editor: Gesundheit Österreich GmbH
  • authors: Sabine Vogler, Peter Schneider, Nina Zimmermann ; unter Mitarbeit von: Manuel Alexander Haasis
1000 Beteiligung
Gesundheit Österreich GmbH (Herausgeber/in) |
1000 Autor/in
  1. Gesundheit Österreich GmbH |
1000 Katalog Id
  • HT020020532
1000 Erscheinungsort Vienna
1000 Verlag Gesundheit Österreich GmbH
1000 Erschienen in Price comparison of high-cost medicines ... , 2017
1000 Art der Datei
1000 Publikationstyp
  1. Monografie |
  2. Report |
1000 FRL-Sammlung
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background and Research Question: Continuous monitoring and analysis of medicine prices support policy-makers in strengthening and further developing pharmaceutical pricing policies. High-cost medicines, i.e. those medicines that account for high public pharmaceutical expenditure, are of particular interest for policy-makers. However, there is no ‚one-size-fits-all‘ approach for the performance of price surveyes and depending on the perspective of a study, different methdological approaches can be chose. The aim of this report is to develop a sound methodological design for conducting a price comparison of medicine prices in European countries. Methods: A literature review was conducted using electronic databases and, in addition, grey literature (e.g. government publications) were also searched via the Internet. Searches combined "price comparison(s)" or "price survey(s)" or "price analysis" with "medicines" or "pharmaceuticals" or "drugs" and several other search terms and their affiliated truncations. Publications were clustered with regard to the chosen methods. Results: Any price comparison in the field pharmaceutical prices needs to address at least 10 dimension: (1) type of price comparison, (2) selection of comparator countries, (3) selection of medicines, (4) price types, (5) data sources an timining, (6) reference pharmaceutical speciality, (7) unit of analysis, (8) exchange rate, and (9) weighting to account for income. Conclusion: Answering these questions may result in different approaches for price comparisons. Given the available information a method has been choosen which seemed most adequate to support Austrian decision makers in the field of pharmaceutical pricing. The different dimension of price comparisons were summarised in a matrix of methods of price comparison to display different approaches for price comparisons.
1000 Sacherschließung
ddc 610 Medizin und Gesundheit
1000 DOI 10.4126/FRL01-006413748 |
1000 Dateien
  1. Price comparison of high-cost medicines ..., 2017
1000 Umfang
  • 1 Online-Ressource (XI, 43 Seiten)
1000 Formschlagwörter
1000 Objektart monograph
1000 Beschrieben durch
1000 @id frl:6413748.rdf
1000 Erstellt am 2019-04-03T09:18:03.268+0200
1000 Erstellt von 25
1000 beschreibt frl:6413748
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Thu May 16 05:48:41 CEST 2019
1000 Objekt bearb. Wed Apr 03 09:18:50 CEST 2019
1000 ähnlich zu
1000 Vgl. frl:6413748
1000 Oai Id
  1. oai:frl.publisso.de:frl:6413748 |
1000 Identisch zu
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Beschrieben durch
1000 Download
1000 Bestand
1000 Lobid

View source